Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK's New Cancer Drug Fund Might Not Alleviate Regional Access Disparities

Executive Summary

The United Kingdom is creating a £600 million Cancer Drugs Fund to improve treatment access but a consultation document on the initiative is doing little to ease concerns about regional disparities in care.

You may also be interested in...



Cancer Drugs Fund Extended As Pharma Calls For U.K. HTA Rethink

Drug manufacturers say the announced two-year extension for Britain’s Cancer Drugs Fund would not have been needed if NICE was not so focused on cost.

NICE Pans Roche’s Perjeta For Breast Cancer On Clinical, Cost Grounds

Roche’s Perjeta suffered a knock-back in Europe when NICE said the clinical trial population was not wholly relevant to the patient population in the UK.

NICE Rejects Roche’s Avastin For Ovarian Cancer Due To Excessive Cost

Roche’s extremely high price for Avastin results in yet another knock-back by Britain’s NICE, this time for advanced ovarian cancer.

Related Content

Topics

UsernamePublicRestriction

Register

PS052790

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel